Aclaris Therapeutics, Inc. ACRS 深 沪
已收盘 09-25 16:00:00 美东时间
5.15
-0.230
-4.28%
华盛通- 最 高5.538
- 今 开5.39
- 成交量 147.41万股
- 最 低 5.095
- 昨 收 5.38
- 总市值 7.58亿
- 52周最高 6.5999
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 1.74
- 委 比 -13.29%
- 总股本 1.47亿
- 历史最高 33.88
- 量 比 0.54
- 振 幅 8.23%
- 历史最低 0.5902
- 每 手 1
- 风险率 1.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
Canaccord Genuity Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $10
Canaccord Genuity analyst Edward Nash initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $10.
09-02 01:46
Vipshop, Gorilla Technology Group And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining over 200 points on Tuesday. Shares of Vipshop Holdings Ltd – ADR (NYSE:VIPS) fell sharply in pre-market trading following second-quarter earnings. Vipshop reported quarterly earnings of 12 cents per share which missed t...
08-25 20:02
Why Cadeler Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S – ADR (NYSE:CDLR) rose sharply in pre-market trading after the company reported interim financial results for the first half of 2026. Revenue for the first six months of 2026 jumped to EUR 408 million from EUR 188 million in the year-ago period. Profit for the period climbed 54...
08-25 17:25
Why Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S – ADR (NYSE:CDLR) rose sharply in pre-market trading after the company reported interim financial results for the first half of 2026. Revenue for the first six months of 2026 jumped to EUR 408 million from EUR 188 million in the year-ago period. Profit for the period climbed 54...
08-25 17:25
High-flyer healthcare stocks: Ten names with strong momentum, weak valuations
Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fu...
08-10 20:49
Aclaris Updates At-The-Market Equity Sales Agreement
Aclaris Therapeutics ( ($ACRS) ) has provided an update. On August 6, 2026, Acl...
08-07 06:22
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics reported Q2 2026 financial results with a net loss of $21.5 million, up from $15.4 million in Q2 2025, driven by increased R&D expenses for ATI-052 and ATI-9494. The company highlighted positive Phase 1a results for its bispecific antibody ATI-052, supporting extended dosing potential, and reaffirmed timelines for upcoming Phase 1b POC trials in asthma and atopic dermatitis. Aclaris also confirmed plans to initiate a Phase 2b...
08-06 10:59
SL Science Holding, Alamos Gold And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Monday. Shares of SL Science Holding Ltd (NASDAQ:SLBT) fell sharply in pre-market trading after the company reported its financial results for the full year ended Dec. 31. Net revenue fell by or 35% to around...
06-22 20:02
美股夜盘 | Sagtec Global Ltd. Class A涨92.93%，LEIFRAS Co涨37.26%
Akanda Corp涨-17.75%；BTQ Technologies涨-11.72%；Aclaris Therapeutics, Inc.涨-11.11%
06-22 08:05
